In this work, liposome-protamine-hyaluronic acid nanoparticles were employed to deliver a siRNA to silence TGF-β expression in tumoral cells while lipid-calcium-phosphate (LCP) nanoparticles were engineered to stimulate DC through the release of tumor antigens and CpG as adjuvants. This evidence concerns the gene TGFB1 and neoplasm.